An indirect treatment comparison of the efficacy of semaglutide 1.0 mg versus dulaglutide 3.0 and 4.5 mg
Open Access
- 19 July 2021
- journal article
- research article
- Published by Wiley in Diabetes, Obesity and Metabolism
- Vol. 23 (11) , 2513-2520
Abstract
Aims Currently no head-to-head trial comparing semaglutide 1.0 mg with dulaglutide 3.0 mg or 4.5 mg exists. An indirect comparison was conducted to compare the effects of semaglutide 1.0 mg versus dulaglutide 3.0 mg and 4.5 mg on glycated haemoglobin (HbA1c) and body weight in patients with type 2 diabetes (T2D). Materials and methods A Bucher indirect comparison was conducted to compare efficacy outcomes of semaglutide 1.0 mg versus dulaglutide 3.0 mg and 4.5 mg using published results from the SUSTAIN 7 and AWARD-11 trials. Sensitivity analyses using individual patient data (IPD) from SUSTAIN 7 and aggregate data from AWARD-11 were conducted to explore the impact of adjustment for cross-trial imbalances in baseline characteristics. Results Semaglutide 1.0 mg significantly reduced HbA1c versus dulaglutide 3.0 mg, with an estimated treatment difference (ETD) of -0.24%-points (95% confidence interval [CI] -0.43, -0.05) with comparable reductions in HbA1c versus dulaglutide 4.5 mg with an ETD of -0.07%-points (95% CI -0.26, 0.12). Semaglutide 1.0 mg significantly reduced body weight versus dulaglutide 3.0 mg and 4.5 mg with an ETD of -2.65 kg (95% CI -3.57, -1.73) and -1.95 kg (95% CI -2.87, -1.03). Sensitivity analyses supported the primary analysis findings. Conclusions This indirect comparison demonstrated significantly greater reductions in HbA1c with semaglutide 1.0 mg versus dulaglutide 3.0 mg and comparable HbA1c reductions versus dulaglutide 4.5 mg. Semaglutide 1.0 mg significantly reduced body weight versus both dulaglutide 3.0 mg and 4.5 mg. With several glucagon-like peptide-1 receptor agonists (GLP-1 RAs) available, information regarding their comparative efficacy can be valuable to clinicians.Keywords
This publication has 14 references indexed in Scilit:
- Exposure‐response analysis for evaluation of semaglutide dose levels in type 2 diabetesDiabetes, Obesity and Metabolism, 2018
- Semaglutide versus dulaglutide once weekly in patients with type 2 diabetes (SUSTAIN 7): a randomised, open-label, phase 3b trialThe Lancet Diabetes & Endocrinology, 2018
- An indirect treatment comparison of the efficacy of insulin degludec/liraglutide (IDegLira) and insulin glargine/lixisenatide (iGlarLixi) in patients with type 2 diabetes uncontrolled on basal insulinJournal of Medical Economics, 2017
- Effects of glucagon‐like peptide‐1 receptor agonists on cardiovascular risk factors: A narrative review of head‐to‐head comparisonsDiabetes, Obesity and Metabolism, 2017
- Obesity and Type 2 Diabetes: Two Diseases with a Need for Combined Treatment Strategies - EASO Can Lead the WayObesity Facts, 2017
- Efficacy and Safety of GLP-1 Receptor Agonists Across the Spectrum of Type 2 Diabetes MellitusExperimental and Clinical Endocrinology & Diabetes, 2017
- Discovery of the Once-Weekly Glucagon-Like Peptide-1 (GLP-1) Analogue SemaglutideJournal of Medicinal Chemistry, 2015
- The importance of weight management in type 2 diabetes mellitusInternational Journal Of Clinical Practice, 2014
- Defining and characterising the progression of type 2 diabetesBritish Journal of Diabetes, 2008
- The results of direct and indirect treatment comparisons in meta-analysis of randomized controlled trialsJournal of Clinical Epidemiology, 1997